
|Articles|April 6, 2023
Live Broadcast: Explore the Efficacy and Safety Data for a Treatment Option for Certain Patients With ESR1-Mutated ER+/HER2- mBC
Advertisement
In an upcoming broadcast, Medical Doctors Hope Rugo and Joyce O'Shaughnessy will discuss important clinical efficacy and safety data for a new treatment option for certain patients with ESR1-mutated, ER+/HER2- mBC following disease progression.
To obtain expert perspective and learn about the efficacy and safety data of this new treatment option, watch the live broadcast on April 25, 2023 and May 1, 2023. To register for the event, visit
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
Subcutaneous Isatuximab Administered Via OBI Approved in EU for Multiple Myeloma
5

































































